BACKGROUND AND OBJECTIVES: Application of local anesthetics may lead to nerve damage. Increasing evidence suggests that risk of neurotoxicity is higher in patients with diabetic peripheral neuropathy. In addition, block duration may be prolonged in neuropathy. We sought to investigate neurotoxicity in vitro and block duration in vivo in a genetic animal model of diabetes mellitus type 2. METHODS: In the first experiments, neurons harvested from control Zucker diabetic fatty (ZDF) rats were exposed to acute (24 hours) or chronic (72 hours) hyperglycemia, followed by incubation with lidocaine 40 mM (approximately 1%). In a second experiment, neurons harvested from control ZDF rats, or diabetic ZDF rats, were incubated with lidocaine, with or without SB203580, an inhibitor of the p38 mitogen-activated protein kinase. Finally, we performed sciatic nerve block (lidocaine 2%, 0.2 mL) in control or diabetic ZDF rats and measured motor and nociceptive block duration. RESULTS: In vitro, neither acute nor chronic hyperglycemia altered neurotoxic properties of lidocaine. In vitro, incubation of neurons with lidocaine resulted in a slightly decreased survival ratio when neurons were harvested from diabetic (57% ± 19%) as compared with control (64% ± 9%) rats. The addition of SB203580 partly reversed this enhanced neurotoxic effect and raised survival to 71% ± 12% in diabetic neurons and 66% ± 9% in control rats, respectively. In vivo, even though no difference was detected at baseline testing, motor block was significantly prolonged in diabetic as compared with control rats (137 ± 16 vs 86 ± 17 min). CONCLUSIONS: In vitro, local anesthetic neurotoxicity was more pronounced on neurons from diabetic animals, but the survival difference was small. In vivo, subclinical neuropathy leads to substantial prolongation of block duration. We conclude that early diabetic neuropathy increases block duration, whereas the observed increase in toxicity was small.
BACKGROUND AND OBJECTIVES: Application of local anesthetics may lead to nerve damage. Increasing evidence suggests that risk of neurotoxicity is higher in patients with diabetic peripheral neuropathy. In addition, block duration may be prolonged in neuropathy. We sought to investigate neurotoxicity in vitro and block duration in vivo in a genetic animal model of diabetes mellitus type 2. METHODS: In the first experiments, neurons harvested from control Zucker diabetic fatty (ZDF) rats were exposed to acute (24 hours) or chronic (72 hours) hyperglycemia, followed by incubation with lidocaine 40 mM (approximately 1%). In a second experiment, neurons harvested from control ZDFrats, or diabeticZDFrats, were incubated with lidocaine, with or without SB203580, an inhibitor of the p38 mitogen-activated protein kinase. Finally, we performed sciatic nerve block (lidocaine 2%, 0.2 mL) in control or diabeticZDFrats and measured motor and nociceptive block duration. RESULTS: In vitro, neither acute nor chronic hyperglycemia altered neurotoxic properties of lidocaine. In vitro, incubation of neurons with lidocaine resulted in a slightly decreased survival ratio when neurons were harvested from diabetic (57% ± 19%) as compared with control (64% ± 9%) rats. The addition of SB203580 partly reversed this enhanced neurotoxic effect and raised survival to 71% ± 12% in diabetic neurons and 66% ± 9% in control rats, respectively. In vivo, even though no difference was detected at baseline testing, motor block was significantly prolonged in diabetic as compared with control rats (137 ± 16 vs 86 ± 17 min). CONCLUSIONS: In vitro, local anesthetic neurotoxicity was more pronounced on neurons from diabetic animals, but the survival difference was small. In vivo, subclinical neuropathy leads to substantial prolongation of block duration. We conclude that early diabetic neuropathy increases block duration, whereas the observed increase in toxicity was small.
Authors: Christine L Oltman; Lawrence J Coppey; Jill S Gellett; Eric P Davidson; Donald D Lund; Mark A Yorek Journal: Am J Physiol Endocrinol Metab Date: 2005-02-22 Impact factor: 4.310
Authors: Jeffrey S Kroin; Asokumar Buvanendran; Dana K Williams; Brian Wagenaar; Mario Moric; Kenneth J Tuman; James M Kerns Journal: Reg Anesth Pain Med Date: 2010 Jul-Aug Impact factor: 6.288
Authors: Philipp Lirk; Ingrid Haller; Hans Peter Colvin; Leopold Lang; Bettina Tomaselli; Lars Klimaschewski; Peter Gerner Journal: Anesth Analg Date: 2008-05 Impact factor: 5.108
Authors: Peter Gerner; Anna E Haderer; Mustafa Mujtaba; Yukari Sudoh; Sanjeet Narang; Salahadin Abdi; Venkatesh Srinivasa; Christof Pertl; Ging Kuo Wang Journal: Anesthesiology Date: 2003-06 Impact factor: 7.892
Authors: Michael R Fettiplace; Katarzyna Kowal; Richard Ripper; Alexandria Young; Kinga Lis; Israel Rubinstein; Marcelo Bonini; Richard Minshall; Guy Weinberg Journal: Anesthesiology Date: 2016-02 Impact factor: 7.892